Scientists and officials from the Food and Drug Administration recently attended a meeting to discuss next steps in research for developing psychedelic drugs.
Multiple FDA representatives spoke at the Reagan-Udall Foundation’s two-day event earlier this month. They discussed the FDA’s efforts to promote clinical studies into the therapeutic potentials of substances like psilocybin or MDMA. The sessions were also attended by academics and professionals involved in psychedelic drug development.
The announcement comes just months after FDA released historic draft guidance on psychedelics research. This provided scientists with a structure to conduct research that could lead them to develop novel medicines.
Patrizia Cazzazzoni of the FDA’s Center for Drug Evaluation and Research, delivered the opening remarks on the first day. She stated that, while psychedelic medicine has not been approved for medical purposes, “we recognize the growing interest in therapeutic potential in psychedelic drugs over the past few years.”
She said that psychedelics were being tested for their potential use as a treatment for a variety of conditions, including depression and post-traumatic disorder. “We also acknowledge that many people use psychedelics in real life, outside of clinical trial.”
Cavazzoni stated that “given these realities, the workshop is a great opportunity to increase our knowledge of psychedelic trial design and to explore considerations of current use of psychoedelics as well as potential future uses of psychedelics.” This type of exploratory discussion on future uses will help to prepare our key partners, and the patients that they serve, for what is next.
Tiffany Farchione from the FDA’s Division of Psychiatry gave a brief overview of FDA’s guidance on psychedelics in clinical trials.
There’s a lot excitement about psychedelics’ potential to transform the treatment for psychiatric disorders and substance abuse disorders, or to simply improve wellbeing, Farchione said. He showed a slide with recent headlines, including Marijuana Moment’s coverage of California’s psychedelics law. “And all of these articles have a general tone of inevitable.” As anyone who has heard me speak about psychedelics knows, putting this cart before the horses from a therapeutic perspective is not a good idea.
During the second day of the event, Farchione spoke at a panel titled “Overview of FDA Regulatory Authority” where she discussed the difficulties of assessing the efficacy of drugs that need interventions other than their direct administration. This complicating factor is brought into play in the context of psychedelics when the substance should be combined with psychotherapy.
We would need to conduct factorial studies to determine the full safety and effectiveness contributions of psychotherapy to psychedelic trial. These studies are expensive and large, and some people argue that not having the therapy is unethical. “We don’t know. A factorial study could be very informative and help us create a better label. But we haven’t done it yet. For now, we are working on the assumption that psychotherapy is needed, but this assumption hasn’t yet been thoroughly evaluated.
Javier Muniz was also a FDA official who spoke on the complexity of psychedelic drug reviews in a panel which examined the concept “set and setting”.
“I’m grateful for all the discussion that is going on, but I will try to bring it a bit back to us as regulators. “At the end of the day, in terms of drug development, how important is setting?” asked the man. “For me, this set and setting issue is closely related to the issues we see in the psychotherapeutic component.”
He said that “in contrast to most other drugs, in a clinical study we don’t usually pay attention to where and how the patient is taking the drug.” For psychedelics there is a greater focus on the way “the context in which this drug is used is heavily influenced by personal and cultural influences.”
Muniz explained that the problem is “that it is highly variable, and there is also a lack a rigourous definition of exactly what this set-up and setting is.”
“We don’t usually make a big fuss about it. This is not something variable. It’s a totally different approach. There are sessions during treatment and then there are the post-integrative session. This is an integral component of the psychotherapeutic process with psychedelics. How do you separate that? What is our top priority, if I were to ask you again? “I think that well-done factorial analyses are absolutely crucial to understanding what these contributions are.”
Bernard Fischer from the FDA and international researchers were on a panel that continued the discussion on the most effective ways to conduct research on plant-based medicine, with a focus on study designs, control conditions, and the FDA.
Background: FDA recently accepted a request to evaluate MDMA-assisted treatment as a treatment option to treat post-traumatic anxiety disorder (PTSD), and agreed to expedite the analysis.
Lykos Therapeutics , formerly MAPS Public Benefit Corporation, submitted the new drugs application. Lykos’ chief scientific officer participated separately in a panel discussion at the Reagan-Udall Foundation Event, along with representatives from the psychedelics-focused companies Compass Pathways & MindMed.
The panel was centered around dosing with substances entheogenic. Researchers from the University of Alabama and University of California San Francisco, as well as Martine Solages, a FDA official, were among those who responded.
The FDA is not the only agency looking at psychedelics. The 2024 National Defense Authorization Act, which President Joe Biden passed into law last year, requires the Department of Defense to spend $10 million to study the therapeutic potential of psilocybin MDMA, ibogaine, and 5-MeO DMT to treat certain mental health issues.
The Department of Veterans Affairs recently released a Request for Applications to Conduct In-Depth Research on the Use of Psychedelics To Treat PTSD And Depression.
Federally Funded Researchers Discover New Methods To Distinguish Hemp and Marijuana For Crime Labs
Photo elements are courtesy carlosemmaskype, and Apollo.
The first time Marijuana Moment featured the post FDA Officials and Experts Discuss Psychedelics Challenges And Promises.
